Concepedia

Author

Pranab Maiti

Jubilant Life Sciences (India)

Also Known As

Pranab Maiti

14

Publications

730

Citations

10

H-Index

42

Concepts

All Affiliations

Jubilant Life Sciences (India)Harvard UniversityEli Lilly (United States)
PM

About

Pranab Maiti is an author at Jubilant Life Sciences (India) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

486

2

Biochemistry

5

5

158

3

Natural Sciences

4

4

184

4

Engineering

1

1

36

5

Health Sciences

1

1

21

Pranab Maiti

×

9

Publications

595

Citations

9

H-Index

YearCitations

A Palmitoylation Switch Mechanism in the Regulation of the Visual Cycle

Linlong Xue, Deviprasad R. Gollapalli, Pranab Maiti,

Cell

2004

137

Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy

Arthur F. Kluge, Bharat Lagu, Pranab Maiti,

Bioorganic & Medicinal Chemistry Letters

2018

122

Small Molecule RPE65 Antagonists Limit the Visual Cycle and Prevent Lipofuscin Formation

Pranab Maiti, Jian Kong, So Ra Kim,

Biochemistry

2005

105

RPE65 Operates in the Vertebrate Visual Cycle by Stereospecifically Binding All-<i>trans</i>-Retinyl Esters

Deviprasad R. Gollapalli, Pranab Maiti, Robert R. Rando

Biochemistry

2003

73

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

Chafiq Hamdouchi, Steven D. Kahl, Anjana Patel Lewis,

Journal of Medicinal Chemistry

2016

58

Stereocontrol of 1,5-related stereocentres using an intermediate silyl group—the diastereoselectivity of nucleophilic attack on a double bond adjacent to a stereogenic centre carrying a silyl group

Ian Fleming, Pranab Maiti, Chandrashekar Ramarao

Organic & Biomolecular Chemistry

2003

36

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus

Chafiq Hamdouchi, Pranab Maiti, Alan M. Warshawsky,

Journal of Medicinal Chemistry

2017

30

A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes

Yanyun Chen, Min Song, Jonathan Riley,

Pharmacology Research & Perspectives

2016

21

Small Molecule RPE65 Antagonists Limit the Visual Cycle and Prevent Lipofuscin Formation,

Pranab Maiti, Jian Kong, So Ra Kim,

Biochemistry

2007

13

Page 1